The Food and Drug Administration last week revised its emergency use authorization for the monoclonal antibody sotrovimab to exclude regions where the COVID-19 omicron BA.2 subvariant predominates, citing new data showing that the authorized dose is unlikely to be effective against this subvariant. 

The excluded regions include Connecticut, Maine, Massachusetts, New Hampshire, New York, New Jersey, Rhode Island, and Vermont, Puerto Rico and the Virgin Islands. 
For more information, see the updated fact sheet for health care providers.

“We will continue to monitor BA.2 in all U.S. regions and may revise the authorization further to ensure that patients with COVID-19 have effective treatments available,” the agency said. 

Related News Articles

Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will…
Headline
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal…
Headline
The Biden Administration will make over 170 million doses of the bivalent COVID-19 vaccine booster available to Americans for free at pharmacies, doctor’s…